REYDEL AUTOMOTIVE GROUP
REYDEL Automotive's mission is to provide innovative quality products to our customers. This mission is stronger than ever as Reydel Automotive aims to be the global automotive supplier of value-added components and systems to vehicle manufacturers around the world. REYDEL Automotive has 15 manufacturing facilities, 4 just-in-time assembly sites and 8 technical centers located in Europe, South America and Asia. Global engineering centers with our R&D teams have the capability to develop new pr... oducts or adapt existing products to local markets. Reydel Automotive has full capability to design, develop and manufacture complete and functional modular interior systems. Our expertise in manufacturing, materials, design and styling allows us to provide innovate, cost-and-weight-efficient products.
REYDEL AUTOMOTIVE GROUP
Industry:
Manufacturing
Address:
Le Plessis-robinson, Ile-de-France, France
Country:
France
Website Url:
http://www.reydel.com
Status:
Active
Technology used in webpage:
SPF SSL By Default LetsEncrypt Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS Ruby On Rails Token AWS Global Accelerator
Official Site Inspections
http://www.reydel.com Semrush global rank: 1.41 M Semrush visits lastest month: 20.11 K
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Reydel Automotive Group"
Erydel - Crunchbase Company Profile & Funding
Erydel develops technology for drug delivery of pharmacological agents through red blood cells. Erydel may be growing as it has been successfully acquired by Quince Therapeutics, which is a significant corporate development indicating …See details»
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
Oct 23, 2023 · Quince’s newly acquired Phase 3 lead asset, EryDex, targets a rare neurodegenerative disease, Ataxia-Telangiectasia (A-T). Currently, there are no approved …See details»
EryDel Company Profile 2024: Valuation, Investors, …
Developer of a non-invasive medical device and therapies designed to facilitate blood processing at the point of care.See details»
Quince Therapeutics to Acquire EryDel
EryDel’s business, operations, and employees into Quince; Quince’s future development plans and related timing; its cash position and projected cash runway; the company’s focus, …See details»
Erydel Company Profile - Office Locations, Competitors, Revenue …
Erydel is a company that develops technology for drug delivery of pharmacological agents through red blood cells. Its proprietary platform technology is an automatic procedure to encapsulate …See details»
EU support for Italian biotech’s red blood cell …
Aug 6, 2020 · The EIB and Italian biotech company EryDel SpA have signed a contract to provide a loan of €30 million to EryDel. This late-stage biotech company aims to develop and commercialise therapies based on its …See details»
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
Oct 30, 2023 · Quince’s latest addition, EryDex, is in Phase 3 development for Ataxia-Telangiectasia (A-T), a rare neurodegenerative disease with no approved treatments, …See details»
Erydel - Contacts, Employees, Board Members, Advisors & Alumni
Erydel has 4 current employee profiles, including Chief Executive Officer and Board Member Luca Benatti. Erydel develops technology for drug delivery of pharmacological agents through red …See details»
EryDel Announces Top-line Results from Phase 3 …
Jul 12, 2021 · EryDel SpA is a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell technology.See details»
Luca Benatti – CEO & Board Member, EryDel - PharmaBoardroom
Feb 17, 2022 · Serial bioentrepreneur Luca Benatti introduces EryDel, an Italian firm based on the concept of using a patient’s red blood cells to deliver drugs. Benatti also weighs in on the …See details»
Ongoing Developments and Clinical Progress in Drug-Loaded Red …
Engineered RBCs have now reached clinical development with some products already in phase III. Leading companies in phase III include EryDel SpA and Erytech Pharma; others have …See details»
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase …
Sep 28, 2023 · Pending the closing of Quince’s acquisition of EryDel, Quince intends to advance the global Phase 3 NEAT (Neurologic Effects of EryDex on Subjects with A-T) clinical trial …See details»
EU support for Italian biotech's red blood cell technology to treat ...
EryDel SpA is a global, late-stage biotech company aiming to use its proprietary red blood cell (RBC) technology to develop and commercialise therapies for the treatment of rare diseases.See details»
FDA Lifts Partial Clinical Hold on IND for EryDel’s Phase 3 Therapy …
Sep 29, 2023 · EryDex utilizes a unique drug/device combination that enables a fully automated process at the point of patient care for the autologous intracellular drug encapsulation of …See details»
FDA lifts partial clinical hold on EryDel lead product EryDex
Sep 28, 2023 · Quince Therapeutics said the FDA has lifted a partial clinical hold on the lead product of its merger partner, EryDel. Phase 3 testing is expected to begin after the deal closes.See details»
EryDel Announces 6 Month Efficacy Results from Phase 3 ATTeST …
EryDel Announces 6 Month Efficacy Results from Phase 3 ATTeST Trial The ATTeST trial was conducted in the United States, Europe, Asia, Australia, and Africa. 175 youngsters with an AT …See details»
EryDel - Innogest
BRESSO, JULY 12th 2021 – EryDel SpA, a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its …See details»
Ongoing Developments and Clinical Progress in Drug-Loaded
Mar 20, 2020 · Most recently, EryDel SpA started a registration program in ataxia telangiectasia patients. The treatment received orphan drug designation by both the US Food and Drug …See details»
EryDel to Present its Phase 3 Study Results for Ataxia …
Apr 5, 2022 · EryDel SpA is a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red …See details»
Ongoing Developments and Clinical Progress in Drug-Loaded Red …
Mar 20, 2020 · Leading companies in phase III include EryDel SpA and Erytech Pharma; others have received FD A and/or EMA clearance for patient recruitment (Rubius TherapeuticsSee details»